Zenas BioPharma, Inc. Common Stock Cash Flow Conversion Efficiency
Zenas BioPharma, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Zenas BioPharma, Inc. Common Stock (ZBIO) has a cash flow conversion efficiency ratio of -0.232x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.24 Million) by net assets ($247.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zenas BioPharma, Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of Zenas BioPharma, Inc. Common Stock from 2022 to 2025. This chart illustrates how Zenas BioPharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ZBIO stock price and chart for real-time trading data and today's change.
Zenas BioPharma, Inc. Common Stock Cash Flow Conversion Ratio Explained
Zenas BioPharma, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zenas BioPharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zenas BioPharma, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see market value of Zenas BioPharma, Inc. Common Stock for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Happen, Inc. Common Stock
NASDAQ:HAPN
|
-0.365x |
|
Bank of Zhengzhou Co Ltd Class A
SHE:002936
|
-0.063x |
|
OFG Bancorp
NYSE:OFG
|
0.028x |
|
Sanxiang Advanced Materials
SHG:603663
|
0.046x |
|
Lianhe Chemical Technology Co Ltd
SHE:002250
|
0.079x |
|
HUTCHMED (China) Limited
F:H7T1
|
-0.071x |
|
Evertec Inc
NYSE:EVTC
|
0.126x |
|
Chin Hin Group Bhd
KLSE:5273
|
0.088x |
Annual Cash Flow Conversion Efficiency for Zenas BioPharma, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Zenas BioPharma, Inc. Common Stock from 2022 to 2025. Review cash generation quality of Zenas BioPharma, Inc. Common Stock to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $242.14 Million | $-172.33 Million | -0.712x | -85.82% |
| 2024-12-31 | $312.46 Million | $-119.67 Million | -0.383x | -383.18% |
| 2023-12-31 | $-225.72 Million | $-30.53 Million | 0.135x | -60.39% |
| 2022-12-31 | $-192.29 Million | $-65.65 Million | 0.341x | -- |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more